ONYX PHARMACEUTICALS INC
DelistedCIK 1012140fmd_04FPQAK8ZAHCA4ZGPV4AWYV09FManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2008 to Jun 30, 2013, 18 periods
| Line item | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 |
|---|---|---|---|---|---|
| Total revenues | 194 | 251 | 325 | 447 | 362 |
| Cost of revenue | – | – | – | – | 1 |
| Gross profit | – | – | – | – | 361 |
| Research and development | 124 | 129 | 186 | 268 | 325 |
| Selling, general and administrative | 81 | 101 | 114 | 168 | 224 |
| Total operating expenses | 205 | 231 | 393 | 349 | 629 |
| Operating income | (10) | 20 | (68) | 98 | (267) |
| Interest expense | 0 | 7 | 19 | 20 | 22 |
| Income before taxes | 2 | 17 | (86) | 76 | (285) |
| Income tax expense | – | 1 | (1) | 0 | (97) |
| Net income from continuing operations | – | 16 | (85) | 76 | (188) |
| Net income | 2 | 16 | (85) | 76 | (188) |
| Net income to common shareholders | – | 16 | (85) | 76 | (188) |